Lv5
1008 积分 2022-02-15 加入
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
7天前
已完结
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
7天前
已完结
Randomized Phase I Trials — One Size Fits All?
1个月前
已完结
Risk factors of cytokine release syndrome: stress, catecholamines, and beyond
1个月前
已完结
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
1个月前
已完结
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
1个月前
已完结
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
1个月前
已完结
Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials
1个月前
已完结
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
1个月前
已完结
Model-Assisted Bayesian Designs for Dose Finding and Optimization
1个月前
已完结
皖公网安备34019202002308
